Literature DB >> 353900

Prostaglandin I2 is less relaxant than prostaglandin E2 on the lamb ductus arteriosus.

F Coceani, E Bodach, E White, I Bishai, P M Olley.   

Abstract

Prostaglandin (PG) I2 and its stable metabolite, 6-keto-PGF1alpha, were tested on the isolated ductus arteriosus from mature fetal lambs. PGI2 relaxed the ductus in high doses (threshold 10(-6)M) and its activity disappeared on standing at room temperature for 30 minutes. 6-keto-PGF1alpha was inactive at all doses. By contrast, PGE2 produced a dose-dependent relaxation over a range between 10(-10) and 10(-6)M. These findings confirm that PGE2 is the most potent ductal relaxant among the known derivatives of arachidonic acid. PGE2 probably maintains ductus patency in the fetus and, together with PGE1, remains the compound of choice in the management of newborns requiring a viable ductus for survival.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 353900     DOI: 10.1016/0090-6980(78)90051-5

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  6 in total

1.  Distribution of prostacyclin synthase, 6-keto-prostaglandin F1 alpha, and 15-hydroxy-prostaglandin dehydrogenase in the normal and persistent ductus arteriosus of the dog.

Authors:  E G de Reeder; A C Gittenberger-de Groot; J C van Munsteren; R E Poelmann; D F Patterson; M J Keirse
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

2.  Endogenous dilator prostaglandins in congenital heart disease.

Authors:  C Hammerman; M J Aramburo; K C Bui
Journal:  Pediatr Cardiol       Date:  1987       Impact factor: 1.655

3.  Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus.

Authors:  H W Seyberth; G Knapp; D Wolf; H E Ulmer
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

4.  Interactions between indomethacin, noradrenaline and vasodilators in the fetal rabbit ductus arteriosus.

Authors:  G C Smith; J C McGrath
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  Patent ductus arteriosus in premature infants: a review of current management.

Authors:  W A Neal; M D Mullett
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

6.  Prostaglandins, ductus arteriosus, pulmonary circulation: current concepts and clinical potential.

Authors:  F Coceani; P M Olley; J E Lock
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.